237 results about "Eukaryotic organism" patented technology

A method for altering the lifespan of a eukaryotic organism. The method comprises the steps of providing a lifespan altering compound, and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using the DeaD assay.

The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject. The invention also provides a method of modulating the growth of muscle tissue or adipose tissue in a eukaryotic organism by administering an agent that affects myostatin signal transduction to the organism.

Methods for determining transcription rate of mRNA in eukaryotic cells using nuclear runoff transcription where labeled RNA molecules are hybridized against an array of at least 500 nucleic acid molecule probes representing at least part of the genome of the native eukaryotic organism to identify the quantity of nascent mRNA transcripts in said cells. The method can be used to simultaneously identify the quantity of a large number of mRNA transcripts. A rate of degradation for distinct mRNA in a eukaryotic cell rate is determined by comparing a steady state mRNA with nuclear runoff mRNA. Steady state to nuclear runoff ratios are used to determine gene and mRNA structure function relations that leads to gene expression and mRNA stability, predict structural determinants for mRNA stability and predict regulatory motifs for transcription rates. Methods of constructing recombinant organisms with enhanced stability for mRNA expressed from a gene of interest comprise introducing into the genome of an organism a gene containing one or more sequence elements that confer structural stability on mRNA transcribed from said gene.

The invention provides methods, compositions and kits for segregating a target nucleic acid from a mixed nucleic acid sample. The methods, compositions and kits comprise a non-processive endonuclease (e.g., a restriction enzyme) or an antibody that binds the target nucleic acid (e.g., has methylation specificity). The mixed nucleic acid sample can comprise prokaryotic and eukaryotic nucleic acid and / or nucleic acid from more than one prokaryotic or eukaryotic organisms.

The invention relates to recombination systems and methods for eliminating nucleic acid sequences from the chromosomal DNA of eukaryotic organisms, and to transgenic organisms—preferably plants—which comprise these systems or were generated using these methods.

Novel Vip3C toxins that are highly active against European corn borer and other lepidopteran insect pests are disclosed. The Vip3C toxins can be expressed in various prokaryotic and eukaryotic organisms including plants to control lepidopteran insects in various environments.

Methods of providing gene suppression DNA in a eukaryotic organism comprising introducing a first DNA segment and at least one second DNA segment into the genome of the organism. One of the DNA segments contains a promoter and a transcribable DNA. Another DNA segment contains at least part of the transcribable DNA. When inserted in tandem, the DNA segments are assembled in vivo forming a recombinant transcription unit. RNA transcribed from the transcription unit can form double-stranded RNA.

The process of System Reconstruction is used to integrate sequence data, clinical data, experimental data, and literature into functional models of disease pathways. System Reconstruction models serve as informational skeletons for integrating various types of high-throughput data. The present invention provides the first metabolic reconstruction study of a eukaryotic organism based solely on expressed sequence tag (EST) data. System Reconstruction also provides a method for the identification of novel therapeutic targets and biomarkers using network analysis. The initial seed networks are built from the lists of novel targets for diseases with the high-throughput experimental data being superimposed on the seed networks to identify specific targets.